The peptide market is strongly impacted by the evolution of the development pipeline, in particular for the treatments that require massive volumes of drugs, driven by the booming demand for metabolic diseases. The scale-up of the existing technology platform to produce synthetic peptides is a major challenge to reach the expected volumes.
The current manufacturing technology platform needs to evolve in order to deliver both sustainable and cost-effective solutions. PolyPeptide is a leading CDMO organization, with the capabilities to efficiently adapt to the emerging requirements and to deliver the most effective and sustainable solutions to develop and manufacture your peptides.

Speaker:

Dr Olivier Ludemann-Hombourger
Global Director Innovation & Technology
PolyPeptide Group

Session Description Coming Soon!

Speakers:

 Dr. Walter Cabri
Full Professor of Chemistry
University of Bologna

Gajan Santhakumar, Ph.D.
Associate Principal Scientist, Early Chemical Development
Astrazeneca

Fernando Albericio
Research Professor
University of Kwazulu-Natal

To accelerate the development of peptides and oligonucleotides as pharmaceuticals, it is important to implement technological developments that overturn traditional approaches and overcome cost and quality challenges in all manufacturing processes, including synthesis, purification, and lyophilization. We will introduce some practical examples of new technologies that can solve these challenges using our model compounds.

Speaker:

Yoshitaka Nemoto
Vice President, R&D Department
PeptiStar Inc.

Effective amidite impurities control is critical in solid phase oligonucleotide synthesis, directly impacting the quality of oligonucleotide API. This presentation will explore the sources and control strategies for various impurities in oligonucleotide API, emphasizing the critical role of amidite impurity control in maintaining API quality. Additionally, the talk will touch upon strategies to establish a resilient supply chain for oligonucleotides, including robust supplies of high quality amidite.

Speaker:

William Fang
Vice President of Oligonucleotide and Peptide Development
WuXi TIDES

This presentation will cover a developability roadmap from a drug delivery and formulation perspective for how to select candidates with a higher chance of success and ways to transform them into a product. The focus will be on injectable peptides but conclude with a perspective on considerations for alternative route delivery.

Speaker:

Annette Bak
Head of Advanced Drug Delivery
Astrazeneca